Examkin

Soru

Zorluk: OrtaPreventive Care and Screening

A 42-year-old biological female presents to the ambulatory clinic for a routine health maintenance examination. She was diagnosed with rheumatoid arthritis five years ago, which is currently well controlled on a regimen of adalimumab and low-dose methotrexate. Her surgical history includes a total abdominal hysterectomy for symptomatic uterine fibroids at age 38. She does not smoke or consume alcohol. Her body mass index is 24 kg/m2, and her blood pressure is 118/74 mmHg. A fasting lipid panel and fasting plasma glucose obtained last month were within normal limits.

Her vaccination records indicate she received an inactivated influenza vaccine one month ago and a tetanus, diphtheria, and acellular pertussis (Tdap) booster four years ago. She has never undergone a colonoscopy. Her most recent screening mammogram was performed eight months ago and showed benign findings.

Which of the following is the most appropriate preventive intervention for this patient at this time?

  1. Administration of a pneumococcal conjugate vaccineCevap
  2. B
    Vaginal vault cytological smear
  3. C
    Administration of the live-attenuated measles, mumps, and rubella vaccine
  4. D
    Screening colonoscopy
  5. E
    Bone mineral density measurement

Cevap

Administration of a pneumococcal conjugate vaccine
The correct intervention is the administration of a pneumococcal conjugate vaccine. This patient is receiving immunosuppressive therapy (adalimumab and methotrexate) for rheumatoid arthritis. The Advisory Committee on Immunization Practices (ACIP) strongly recommends pneumococcal vaccination for adults aged 19 to 64 years with immunocompromising conditions, which includes iatrogenic immunosuppression. Due to her medication regimen, she is at elevated risk for invasive pneumococcal disease and should receive a pneumococcal conjugate vaccine.

Adım Adım Çözüm

1
Analyze the patient's medical history and current medication regimen.
The patient has rheumatoid arthritis treated with adalimumab (a TNF-alpha inhibitor) and methotrexate.
Identifying the use of these medications is critical to recognizing that the patient has an iatrogenic immunocompromising condition.
2
Evaluate the patient's age and vaccination status against ACIP guidelines for immunocompromised individuals.
Although she is 42 (below the routine age-based cutoff of 50 for pneumococcal vaccination), her immunosuppressive therapy mandates vaccination with a pneumococcal conjugate vaccine to prevent invasive disease.
Guidelines explicitly recommend pneumococcal vaccination for adults aged 19-64 with conditions causing altered immunocompetence, including immunosuppressive drug therapy.
3
Assess the appropriateness of the remaining preventive care options based on age, surgical history, and medication contraindications.
Colonoscopy is premature (starts at 45), bone density measurement is premature (starts at 65 without major steroid use), vaginal cytology is unnecessary (post-benign hysterectomy), and live vaccines (MMR) are contraindicated.
Systematically ruling out the distractors ensures that pneumococcal vaccination is the singular most appropriate next step.

Anahtar Kavram

Adults aged 19-64 with iatrogenic immunosuppression (e.g., TNF-alpha inhibitors, methotrexate) require vaccination against pneumococcal disease and must avoid all live-attenuated vaccines.
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru